Challenges in molecular analysis for individualized cancer therapy

Drug Discovery Today

Volumn 8, Issue 12, 2003, Pages 531-

  Clynes, Martin ^a   O'Connor, Robert ^a   O'Driscoll, Lorraine ^a   Daly, Carmel ^a   Meleady, Paula ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Cancer; Cancer biology; Cell biology; Chemotherapy; Drug Discovery; Molecular Medicine; Pharmaceutical Science; Tumour

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER THERAPY; CHEMOREACTIVITY; DNA MICROARRAY; DRUG CLEARANCE; DRUG METABOLISM; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; LABORATORY TEST; METASTASIS; MULTIDRUG RESISTANCE; PREDICTION; SHORT SURVEY; SIDE EFFECT; THERAPY RESISTANCE; TUMOR CELL; TUMOR GROWTH; VASCULARIZATION;

EID: 0038122881     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02730-2     Document Type: Note

References (6)

1. Clynes M. Multiple Drug Resistance in Cancer 2. 1998;Kluwer Academic Publishers.
2. Huang Y., Sadée W. Drug sensitivity and resistance genes in cancer chemotherapy; a chemogenomics approach. Drug Discov. Today. 8:2003;356-363.
3. Petricoin E.F., et al. Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst. 94:2002;1576-1578.
4. Wulfkuhle J.D., et al. New approaches to proteomic analysis of breast cancer. Proteomics. 1:2001;1205-1215.
5. Fleischhacker M., et al. Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann. New York Acad. Sci. 945:2001;179-188.
6. Liang Y., et al. Examining the relationship between cancer invasion/metastases and drug resistance. Cancer Drug Targets. 2:2002;257-277.